CEO Reshma Kewalramani detailed Vertex Pharmaceuticals' expansion beyond cystic fibrosis at the Morgan Stanley 24th Annual Global Healthcare Conference. The strategy prioritizes a new renal medicine portfolio alongside advancements in gene editing, acute pain, and rare endocrine programs.
The company faces a November 30 PDUFA date for povetacicept to treat IgA nephropathy. Vertex also expects upcoming data readouts for inaxaplin in APOL1-mediated kidney disease.
Vertex has already engaged with over 70% of U.S. payers regarding povetacicept. Management acknowledged inherent development risks, including regulatory approvals and clinical trial outcomes. Vertex shares traded 1.06% lower in the premarket session.